Dr. Silva is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
80 Broadway Ste 2d
Cresskill, NJ 07626Phone+1 201-218-1380Fax+1 212-263-0202
Education & Training
NYU Grossman School of MedicineFellowship, Child and Adolescent Psychiatry, 1990 - 1992
Icahn School of Medicine at Mount Sinai/St Luke’s-Roosevelt Hospital CenterFellowship, Child and Adolescent Psychiatry, 1988 - 1990
Richmond University Medical CenterResidency, Psychiatry, 1984 - 1988
Ross University School of MedicineClass of 1983
Certifications & Licensure
NJ State Medical License 2007 - 2025
NY State Medical License 1989 - 2017- American Board of Psychiatry and Neurology Psychiatry
- American Board of Psychiatry and Neurology Child & Adolescent Psychiatry
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2012-2014
Publications & Presentations
PubMed
- 5 citationsExtended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity ...Raul R. Silva, Matthew Brams, Kevin McCague, Linda Pestreich, Rafael Muniz
Clinical Neuropharmacology. 2013-07-01 - 79 citationsFactors Related to Posttraumatic Stress Disorder in AdolescenceKate B. Nooner, L. Oriana Linares, Jessica Batinjane, Rachel Kramer, Raul R. Silva
Trauma, Violence & Abuse. 2012-06-04 - 12 citationsCardiovascular Safety of Stimulant Medications for Pediatric Attention-Deficit Hyperactivity DisorderRaul R. Silva, Jeffrey W. Skimming, Rafael Muniz
Clinical Pediatrics. 2010-09-01
Press Mentions
Cingulate Announces Positive Fed/Fast Study Results of CTx-1301 ADHD Lead AssetFebruary 23rd, 2023- Cingulate Completes Phase 3 Adult Trial of CTx-1301 (Dexmethylphenidate) for ADHDJune 9th, 2023
- Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of ...September 12th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
